Head-To-Head Comparison: Athenex (ATNX) versus Its Competitors
Athenex (NASDAQ: ATNX) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Athenex to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.
Insider & Institutional Ownership
3.1% of Athenex shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Athenex and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Athenex and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Athenex Competitors||$290.27 million||$35.99 million||62.10|
Athenex’s competitors have higher revenue and earnings than Athenex.
This is a summary of current recommendations for Athenex and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Athenex currently has a consensus price target of $27.64, indicating a potential upside of 59.49%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.78%. Given Athenex’s stronger consensus rating and higher probable upside, research analysts plainly believe Athenex is more favorable than its competitors.
Athenex beats its competitors on 6 of the 10 factors compared.
Athenex Company Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company’s Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.